Cedars-Sinai Cancer Experts Available to Discuss ASCO 2023 News

Cedars-Sinai Cancer physician-scientists with expertise in liver, skin, lung, breast, colorectal, pancreatic, brain, prostate and endometrial cancers will be attending the American Society of Clinical Oncology annual meeting June 2-6 in Chicago and are available for in-person or virtual interviews to discuss the latest news and research.

Markey Cancer Center study identifies new treatment target for metastatic cancer

A new University of Kentucky Markey Cancer Center study reveals more about changes that happen to cancer cells when they metastasize and identifies a promising target for the treatment of metastatic breast cancer.Metastasis is when cancer cells spread from the primary tumor to surrounding tissues and distant organs in the body and is the primary cause for breast cancer mortality.

Living Beyond Breast Cancer to Host 17th Annual Thriving Together Conference on Metastatic Breast Cancer April 28–30, 2023 in Philadelphia

Living Beyond Breast Cancer’s Thriving Together 2023 Conference on Metastatic Breast Cancer, the nation’s premier and longest-running conference for people affected by stage IV breast cancer, will be held April 28–30, 2023 at the Hilton Philadelphia at Penn’s Landing as well as virtually.

Prompt Recognition and Treatment Found Effective for Lung Disease in Patients Who Received New Drug for Advanced Cancer

Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open on August 11, 2022.

Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer

A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. This is the first demonstration of a survival advantage with a front-line CDK4/6 inhibitor in postmenopausal patients with
HR+/HER 2- advanced breast cancer.

Expert Breast Cancer Treatment Recommendations Based on Latest Evidence Updating for Multiple Languages

Ongoing updates are underway for NCCN Guidelines for Breast Cancer in Chinese, English, French, Japanese, Korean, Spanish, Polish, and Portuguese, free online at NCCN.org/global. Follow #NCCNGlobal for more. The NCCN Foundation is hosting free metastatic breast cancer webinars for patients and caregivers on October 8 and 12 at NCCN.org/patients.

Study finds no overall survival benefit, but improved quality of life with talazoparib in advanced BRCA-mutated breast cancer

New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to receive subsequent systemic therapies, which may have affected the survival outcome analysis. The research confirmed previous results showing talazoparib improved patient reported quality-of-life measures over available chemotherapies and had a tolerable safety profile.

NCCN Announces Projects Funded for Metastatic Breast Cancer Grant Program, in Collaboration with Pfizer

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces proposals selected for funding, in collaboration with Pfizer Global Medical Grants, to improve the quality of care and outcomes for people with metastatic breast cancer (MBC).

Mayo Clinic to host Sixth Annual Metastatic Breast Cancer Conference

Mayo Clinic will host the Sixth Annual Metastatic Breast Cancer Conference at the Omni Scottsdale Resort and Spa at Montelucia in Scottsdale, Arizona, Sept. 19–20. This program is a joint effort among Mayo Clinic, Baylor College of Medicine, and Theresa’s…